Green method for synthesizing chiral norpseudoephedrine intermediate
Synthesis of chiral epoxy alcohol compounds under aqueous phase conditions through P450 monooxygenase bienzyme cascade reaction, solving the problems of harsh reaction conditions and poor stereoselectivity in the prior art, and achieving efficient and environmentally friendly biosynthesis , with high catalytic activity and easy operation.
Patent Information
- Application Number
- CN202411386644.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-19
AI Technical Summary
The existing chiral epoxy alcohol compound synthesis technology has problems such as the use of transition metal catalysis, many by-products, poor stereoselectivity, and harsh reaction conditions. There is a lack of synthesizer enzymes for chiral epoxy alcohol compounds with high activity and high stereoselectivity. , it is difficult to achieve efficient biocatalytic preparation.
The no-pseudoephedrine intermediate (R,R)-epoxy alcohol compound and norephedrine intermediate (S,R) were synthesized under aqueous phase conditions using P450 monooxygenase P450DA-M1 and P450PL 1 bienzyme cascade reactions. - Epoxy alcohol compound, constructs and induces the expression of P450 monooxygenase through genetic engineering, realizes catalysis of the dual enzyme cascade reaction, avoids the use of transition metals and toxic reagents, and performs biosynthesis at room temperature and normal pressure.
The biosynthesis of chiral epoxy alcohol compounds with high reaction rate, short time consumption and environmentally friendly has been achieved, with high catalytic activity and simple operation, and solves the problems of poor stereoselectivity and harsh reaction conditions in the prior art.
Smart Images

Figure CN118979020A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of synthesis of chiral epoxy alcohol compounds, and in particular to a method for synthesizing a norephedrine intermediate (R, R)-epoxy alcohol compound by a double enzyme cascade reaction of P450 monooxygenase P450DA-M1 and P450PL1, and an application of a method for synthesizing a norephedrine intermediate (S, R)-epoxy alcohol compound by a double enzyme cascade reaction of P450 monooxygenase P450DA-M1 and P450DA-M2. Background Art
[0002] Chiral epoxy alcohol compounds are a very important class of compounds that can be used as important intermediates and catalysts for the drug (pseudo)ephedrine and are widely used in organic synthesis and drug synthesis. The existing synthesis technology of chiral epoxy alcohol compounds still has shortcomings such as the use of transition metal catalysis, many by-products, poor stereoselectivity, and harsh reaction conditions. The high efficiency and high selectivity of bioenzymes make biocatalysis technology expected to develop into a new way for the industrial green preparation of chiral epoxy alcohol compounds. However, existing studies have shown that chiral epoxy alcohol compound synthases with high activity and high stereoselectivity are still very scarce. Therefore, obtaining bioenzymes with high catalytic efficiency and corresponding biocatalytic synthesis methods is still a difficulty in the development of biocatalytic preparation of chiral epoxy alcohol compounds. Summary of the invention
[0003] The purpose of the present invention is to provide a P450 monooxygenase P450DA-M1 and P450PL 1 dual enzyme cascade reaction to synthesize a norephedrine intermediate (R, R)-epoxy alcohol compound, and an application of a P450 monooxygenase P450DA-M1 and P450DA-M2 dual enzyme cascade reaction to synthesize a norephedrine intermediate (S, R)-epoxy alcohol compound to solve the above technical problems.
[0004] The technical solution of the present invention:
[0005] A preparation method of a chiral epoxy alcohol compound of a nor(pseudo)ephedrine intermediate is characterized by using allylbenzene as a substrate, a P450 monooxygenase P450DA-M1 and a P450PL 1 double enzyme cascade reaction to synthesize a nor(pseudo)ephedrine intermediate (R,R)-epoxy alcohol compound, and a P450 monooxygenase P450DA-M1 and a P450DA-M2 double enzyme cascade reaction to synthesize a nor(pseudo)ephedrine intermediate (S,R)-epoxy alcohol compound, and reacting under aqueous phase conditions, the reaction formula is as follows:
[0006] in:
[0007] R is fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, phenyl, methylphenyl, methoxyphenyl, bromophenyl, chlorophenyl, or fluorophenyl.
[0008] The present invention is achieved in that:
[0009] In the first aspect, the present invention provides a P450 monooxygenase P450DA-M1, whose amino acid sequence is shown in SEQ ID No.1; the present invention provides a monooxygenase P450DA-M2, whose amino acid sequence is shown in SEQ ID No.3; the present invention provides a monooxygenase P450PL-M1, whose amino acid sequence is shown in SEQ ID No.5.
[0010] The P450 monooxygenase P450DA-M1, P450DA-M2 and P450PL-M1 genes of the present invention are constructed into genetic engineering bacteria, and induced to express to obtain P450 monooxygenase. It is found that the P450 monooxygenase has the function of catalyzing allylbenzene to synthesize chiral epoxy alcohol compounds in a double enzyme cascade reaction. Compared with the existing preparation method of chiral epoxy alcohol compounds, the use of the dual enzyme cascade reaction provided by the present invention to biosynthesize chiral epoxy alcohol compounds has the technical advantages of high reaction rate, no need for intermediate separation and short time consumption; the dual enzyme cascade reaction of a P450 monooxygenase P450DA-M1 and P450PL1 provided by the present invention to synthesize a demethylpseudoephedrine intermediate (R, R)-epoxy alcohol compound, and the dual enzyme cascade reaction of a P450 monooxygenase P450DA-M1 and P450DA-M2 to synthesize a demethylpseudoephedrine intermediate (S, R)-epoxy alcohol compound can be carried out at room temperature, normal pressure and in an aqueous environment, and the reaction conditions are mild; in addition, the P450 monooxygenase dual enzyme cascade provided by the present invention does not need to use transition metals or toxic reagents when synthesizing chiral epoxy alcohol compounds, so the P450 monooxygenase dual enzyme cascade provided by the present invention has high catalytic activity, is environmentally friendly, and is easy to operate.
[0011] The amino acid sequence of monooxygenase P450DA-M1 shown in SEQ ID No. 1 is as follows:
[0012] In a second aspect, the present invention further provides an isolated nucleic acid molecule encoding the above-mentioned monooxygenase P450DA-M1, wherein the isolated nucleic acid molecule has a nucleotide sequence as shown in SEQ ID No. 2:
[0013] In a third aspect, the present invention provides a monooxygenase P450DA-M2, the amino acid sequence of which is shown in SEQ ID No. 3;
[0014] The present invention also provides an isolated nucleic acid molecule encoding the above-mentioned monooxygenase P450DA-M2, and the isolated nucleic acid molecule has the nucleotide sequence shown in SEQ ID No. 4 as follows:
[0015] In a fourth aspect, the present invention provides a monooxygenase P450PL-M1, whose amino acid sequence is shown in SEQ ID No.5:
[0016] The present invention also provides an isolated nucleic acid molecule encoding the above-mentioned monooxygenase P450PL-M1, and the isolated nucleic acid molecule has the nucleotide sequence shown in SEQ ID No.6 as follows:
[0017] In a fifth aspect, the present invention also provides a vector comprising the above-mentioned nucleic acid molecule.
[0018] The vector includes but is not limited to bacterial expression vectors, fungal expression vectors, etc., as long as the vector can achieve the expression of the above-mentioned nucleic acid molecules and the shuttle of the above-mentioned nucleic acid molecules. Including but not limited to plasmids, etc. Bacterial expression vectors such as Escherichia coli expression vectors, Streptomyces or Mycobacterium expression vectors. Fungal expression vectors such as yeast vectors. In a sixth aspect, the present invention also provides a recombinant bacterium, which comprises the above-mentioned vector. In a preferred embodiment of the present invention, the recombinant bacteria are bacteria or fungi; In a preferred embodiment of the present invention, the bacteria are Escherichia coli, Streptomyces or Mycobacterium.
[0019] Fungi such as yeast.
[0020] In a preferred embodiment of the present invention, the recombinant bacteria refers to at least one of resting cells of bacteria, living cells of recombinant bacteria, dead cells of recombinant bacteria, and cell fragments of recombinant bacteria.
[0021] The above-mentioned recombinant bacteria (or genetically engineered bacteria) are obtained by transforming a recombinant expression vector into a host microorganism by conventional methods in the art; the host microorganism can be various conventional host microorganisms in the art, as long as the recombinant expression vector can stably replicate itself and the P450 monooxygenase and epoxide hydrolase genes carried by it can be effectively expressed; preferably, it can be obtained by the following method: transforming the recombinant vector pET-28a(+)-P450 into Escherichia coli BL21(DE3).
[0022] Dormant cells, also known as resting cells, are a special cell state. In this state, cells do not grow and reproduce, but still contain various enzyme systems and have oxidation and fermentation capabilities. Under suitable conditions, dormant cells can resume growth. The characteristics of dormant cells include: a. Cells maintain growth potential: Although in a dormant state, these cells can re-enter the cell cycle and restore their proliferation ability when given appropriate stimulation. b. Strong specificity: Dormant cells have strong specificity in the reaction and can improve the substrate conversion rate. c. Not easy to be contaminated by foreign bacteria: Due to its characteristics, dormant cells can reduce the inhibition of bacterial growth and enzyme synthesis by products during use.
[0023] In a seventh aspect, the present invention also provides the use of P450 monooxygenase, recombinant bacteria, recombinant cells, immobilized enzymes or immobilized cells in the biosynthesis of chiral epoxy alcohol compounds.
[0024] The P450 monooxygenase includes, but is not limited to, purified recombinant P450 monooxygenase protein and crude enzyme solution containing P450 monooxygenase.
[0025] The above-mentioned P450 monooxygenase, recombinant bacteria, recombinant cells, immobilized enzymes or immobilized cells can efficiently, quickly and simply realize the biosynthesis of chiral epoxy alcohol compounds at room temperature, normal pressure and in an aqueous environment. The entire synthesis process is environmentally friendly and has broad application prospects.
[0026] In a preferred embodiment of the present invention, the substrate for the biosynthesis of chiral epoxy alcohol compounds is an allylbenzene compound.
[0027] In an eighth aspect, the present invention also provides a method for biosynthesizing chiral epoxy alcohol compounds, using the above-mentioned P450 monooxygenase, bacteria, cells and substrates to react.
[0028] In a preferred embodiment of the present invention, the reaction temperature is 0-50° C.; at the above reaction temperature, the biosynthesis efficiency of chiral epoxy alcohol compounds is relatively high.
[0029] In a preferred embodiment of the present invention, 10-50 mM of substrate is mixed with 5-25 mL of P450 monooxygenase, bacteria, cells, immobilized enzyme or immobilized cells.
[0030] For example, 10-20 mM, 10-25 mM, 30-40 mM or 35-50 mM of substrate is mixed with 5-10 mL, 15-25 mL or 20-25 mL of P450 monooxygenase, bacteria, cells, immobilized enzyme or immobilized cells.
[0031] In a preferred embodiment of the present invention, P450 monooxygenase and epoxide hydrolase, bacteria, cells, immobilized enzyme or immobilized cells are placed in a buffer, mixed with a substrate and reacted on a shaker at 200-250 rpm.
[0032] In a preferred embodiment of the present invention, the reaction product is extracted with an organic solvent, and the chiral epoxy alcohol compound is obtained by column chromatography. In an optional embodiment, the organic solvent is selected from an organic solvent that is easily compatible with the chiral epoxy alcohol compound, such as an ester. The ester is such as ethyl acetate. The chiral epoxy alcohol compound is obtained by column chromatography after purification.
[0033] In a preferred embodiment of the present invention, the buffer is a sodium phosphate buffer with a concentration of 50-200 mM and a pH of 6-9.
[0034] The beneficial effects of adopting the above technical solution are:
[0035] The present invention provides a method for synthesizing a norephedrine intermediate (R, R)-epoxy alcohol compound by a double enzyme cascade reaction of P450 monooxygenase P450DA-M1 and P450PL 1, and a method for synthesizing a norephedrine intermediate (S, R)-epoxy alcohol compound by a double enzyme cascade reaction of P450 monooxygenase P450DA-M1 and P450DA-M2. Compared with the existing method for preparing chiral epoxy alcohol compounds, the method for biosynthesizing chiral epoxy alcohol compounds by using the double enzyme cascade reaction of P450 monooxygenase provided by the present invention has the technical advantages of high reaction rate and short time consumption.
[0036] The P450 monooxygenase double enzyme cascade reaction provided by the present invention can be carried out at room temperature, normal pressure and in an aqueous environment when synthesizing chiral epoxy alcohol compounds, and the reaction conditions are mild. In addition, the P450 monooxygenase double enzyme cascade reaction provided by the present invention does not require the use of a strong oxidant, a metal catalyst or a toxic reagent when synthesizing chiral epoxy alcohol compounds. Therefore, the P450 monooxygenase double enzyme cascade reaction provided by the present invention has high catalytic activity, is environmentally friendly, is easy to operate, and has broad application prospects. DETAILED DESCRIPTION
[0037] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0038] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0039] The features and performance of the present invention are further described in detail below in conjunction with the embodiments. Example 1
[0040] This embodiment provides a method for obtaining P450DA-M1 monooxygenase, which specifically comprises the following steps:
[0041] After the genetically engineered bacteria BL21 (DE3) containing the recombinant plasmid stored in glycerol was activated by streaking a plate, a single colony was picked and placed in 5 ml of liquid LB medium containing the corresponding antibiotics, and cultured at 37°C with shaking for 12 h. The next day, the colony was transferred to 100 mL of fresh LB liquid medium containing antibiotics at a 1% inoculum and cultured at 37°C with shaking at 250 rpm until the OD 600 The concentration of IPTG was 0.6 (about 3 hours), and IPTG was added to a final concentration of 0.2 mM, and the culture was induced at 25°C and 160 rpm for 8 hours. After the induction, the cells were collected by centrifugation at 5000 rpm / min for 5 minutes, and the cells were resuspended in PBS buffer to obtain the monooxygenase P450DA-M1 catalyst. Example 2
[0042] This embodiment provides a method for obtaining P450PL-M1 monooxygenase, which specifically comprises the following steps:
[0043] After the genetically engineered bacteria BL21 (DE3) containing the recombinant plasmid stored in glycerol was activated by streaking a plate, a single colony was picked and placed in 5 ml of liquid LB medium containing the corresponding antibiotics, and cultured at 37°C with shaking for 12 h. The next day, the colony was transferred to 100 mL of fresh LB liquid medium containing antibiotics at a 1% inoculum and cultured at 37°C with shaking at 250 rpm until the OD 600The concentration of IPTG was 0.6 (about 3 hours), and IPTG was added to a final concentration of 0.2 mM, and the culture was induced at 20°C and 160 rpm for 8 hours. After the induction, the cells were collected by centrifugation at 5000 rpm / min for 5 minutes, and the cells were resuspended in PBS buffer to obtain the monooxygenase P450PL-M1 catalyst. Example 3
[0044] The wet cells of the strains cultured in Example 1 and Example 2 were suspended in 5 mL of PBS buffer with a pH of 8.0 at a cell concentration of 20 g / L. A 10 mM concentration of substrate allylbenzene was added to the above 5 mL reaction system, and the mixture was placed in a shaker at 20°C and 250 rpm for 24 hours. Ethyl acetate was then added for extraction. 20 bottles of organic phases after extraction were collected, dried over anhydrous sodium sulfate, centrifuged to remove sodium sulfate and filtered. The solvent was evaporated under pressure, and the chiral vicinal diol compound was obtained by silica gel column chromatography. Product detection data: yield was 39%, ee value was 90%, (Chiral AS-H, hexane / i-PrOH = 90 / 10, flow rate = 1.0 mL / min, λ = 210 nm, retention time: t (R)-6a =12.201min,t (S)-6a =14.797min),[α] D 25 =47.8(c=0.525,CH 2 Cl 2 ). 1 H NMR (400 MHz, DMSO-D 6 ): δ7.30-7.09(m,5H),4.54(t,J=6.0Hz,2H),3.64-3.53(m,1H),3.29-3.18(m,2H),2.73(dd,J=13.6,4.8Hz,1H),2.51(d,J=7.9Hz,1H). 13 C NMR (100 MHz, DMSO-D 6 ):δ140.1,129.8,128.4,126.1,72.9,65.7,39.9.HRMS(ESI-TOF)Calcd.for C 9 H 12 O 2 Na[M+Na] + :175.0735; found:175.0741.
[0045] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A P450 monooxygenase, Features: The amino acid sequence of P450DA-M1 is shown in SEQ ID No. 1; The amino acid sequence of P450DA-M2 is shown in SEQ ID No. 3; The amino acid sequence of P450PL-M1 is shown in SEQ ID No.
5.
2. Isolated nucleic acid molecules, Features: It encodes the P450 monooxygenase according to claim 1.
3. A carrier, Features: It comprises the nucleic acid molecule according to claim 2.
4. A recombinant bacterium, Features: It comprises the vector according to claim 3; The recombinant bacteria are bacteria or fungi; The bacteria is Escherichia coli, Streptomyces or Mycobacterium; The recombinant bacteria refers to at least one of resting cells of the recombinant bacteria, living cells of the recombinant bacteria, dead cells of the recombinant bacteria, and cell fragments of the recombinant bacteria.
5. A recombinant cell, Features: It comprises the vector according to claim 3, and the recombinant cell is an insect cell.
6. An immobilized cell, Features: The recombinant bacteria according to claim 4 or the recombinant cells according to claim 5 are fixed; The method of cell fixation via the carrier is selected from at least one of an adsorption method, a covalent binding method, a cross-linking method, and a microencapsulation method; The immobilized cells are live or dead bacteria.
7. Use of the P450 monooxygenase according to claim 1, the recombinant bacteria according to claim 4, the recombinant cell according to claim 5, and the immobilized enzyme according to claim 6 in the biosynthesis of chiral epoxy alcohol compounds.
8. The use according to claim 7, Features: The substrate for biosynthesis of the chiral epoxy alcohol compound is allylbenzene.
9. A method for biosynthesizing chiral epoxy alcohol compounds, Features: Using the P450 monooxygenase of claim 1, the recombinant bacteria of claim 4, the recombinant cell of claim 5, the immobilized enzyme of claim 6 to react with a substrate; The reaction temperature is 0-50°C; Mixing 10-50 mM of the substrate with 5-25 mL of the P450 monooxygenase, the bacteria, the cells, the immobilized enzyme or the immobilized cells; The P450 monooxygenase, the recombinant bacteria, the recombinant cells, the immobilized enzyme or the immobilized cells are placed in a buffer, mixed with the substrate, and reacted on a shaker at 200-250 rpm; The reaction product is extracted with an organic solvent, and a chiral epoxy alcohol compound is obtained by column chromatography analysis; The buffer is a sodium phosphate buffer with a concentration of 50-200 mM and a pH of 6-9.
10. A method for preparing a chiral epoxy alcohol compound as a nor(pseudo)ephedrine intermediate, Features: Allylbenzene is used as a substrate, a P450 monooxygenase P450DA-M1 and P450PL 1 double enzyme cascade reaction is used to synthesize a norephedrine intermediate (R, R)-epoxy alcohol compound, and a P450 monooxygenase P450DA-M1 and P450DA-M2 double enzyme cascade reaction is used to synthesize a norephedrine intermediate (S, R)-epoxy alcohol compound, and the reaction is carried out under aqueous phase conditions. The reaction formula is as follows: in: R is fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, phenyl, methylphenyl, methoxyphenyl, bromophenyl, chlorophenyl, or fluorophenyl.
